The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Age-Related Macular Degeneration Market In 2026 And 2030?
The age-related macular degeneration market has experienced substantial expansion in recent years. It is anticipated to increase from $10.67 billion in 2025 to $11.46 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. The historical growth of this market can be linked to a global aging population, the rising prevalence of AMD, previously limited treatment options, increased awareness of eye health, and the expansion of hospital and ophthalmology clinic infrastructure.
The age-related macular degeneration market size is anticipated to expand significantly over the next few years. It is expected to reach $15.42 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period can be linked to factors such as the development of next-generation anti-VEGF drugs, increasing investment in ophthalmology research, the proliferation of specialty pharmacies and online pharmacy channels, a growing application of combination therapies, and the rising adoption of personalized treatment approaches. Key trends for the forecast period involve the increasing embrace of anti-VEGF therapies, a rising use of nutritional supplements and low vision aids, an increase in photodynamic and laser therapy procedures, the expansion of intravitreal and intravenous administration routes, and heightened awareness coupled with regular eye screening programs.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Important Drivers Are Guiding The Age-Related Macular Degeneration Market Growth?
The increasing prevalence of age-related macular degeneration (AMD) is expected to boost the growth of the age-related macular degeneration (AMD) market in the future. Age-related macular degeneration (AMD) is an advancing eye condition that affects the macula, a vital part of the retina responsible for central vision. Treatments for age-related macular degeneration (AMD) assist patients with retinal disorders by mitigating the intensity of the disease. For instance, in February 2023, according to reports provided by Optimaxa, a UK-based laser eye treatment specialist, age-related macular degeneration (AMD) impacted 196 million individuals globally and is forecast to reach 288 million in 2040, accounting for 8.7 percent of the world’s population. Therefore, the rising prevalence of age-related macular degeneration (AMD) is a key driver for the age-related macular degeneration market.
What Are The Main Segments Within The Age-Related Macular Degeneration Market Segment Structure?
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Drugs
3) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
What Trends Are Influencing The Evolution Of The Age-Related Macular Degeneration Market?
Leading companies in the age-related macular degeneration (AMD) market are pushing forward with advanced technologies, including recombinant antigen-binding fragments. Recombinant antigen-binding fragments (Fab) are specialized proteins created from antibodies that selectively attach to specific target antigens, frequently utilized in medical treatments to impede disease-related processes. For instance, in December 2023, Enzene Biosciences, an Indian biotechnology company, released ranibizumab, which is a recombinant monoclonal antibody fragment (Fab) specifically designed to block vascular endothelial growth factor (VEGF), a primary protein involved in the growth of abnormal blood vessels in conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). Through its action of obstructing VEGF, ranibizumab effectively minimizes the leakage and growth of these blood vessels, thus aiding in vision preservation for patients with these eye conditions. Administered via intravitreal injection, it has gained extensive recognition in clinical settings for its effectiveness in managing various retinal ailments. The launch of ranibizumab has substantially improved the treatment options available for patients dealing with these serious disorders.
Who Are The Companies Participating In The Age-Related Macular Degeneration Market?
Major companies operating in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Outlook Therapeutics Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.
Get The Full Age-Related Macular Degeneration Market Report:
Which Region Represents The Largest Share Of The Age-Related Macular Degeneration Market?
North America was the largest region in the global age-related macular degeneration market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Age-Related Macular Degeneration Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Age-Related Macular Degeneration Market 2026, By The Business Research Company
Non Proliferative Diabetic Retinopathy Market Report 2026
Macular Degeneration Treatment Market Report 2026
Macular Edema And Macular Degeneration Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model